Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:
In May, Apellis Pharmaceuticals (APLS) secured U.S. approval for a drug called Empaveli to treat patients with a rare blood condition. The company is now looking to expand the use of the medicine to help people with geographic atrophy, an age-related condition that leads to the breakdown of the macula — an important part of a person’s retina. Results from twin Phase 3 clinical trials of Empaveli in patients with geographic atrophy are coming this quarter. With nearly 1 million people diagnosed with the eye disease, analysts predict the drug could bring in more than $1 billion in revenue annually for Apellis, if it wins an expanded label.